| 131I-组合单克隆抗体局部放射免疫导向治疗肝癌的临床观察 |
| |
| 引用本文： | 蔡红兵,罗荣城,李爱民,张军一,廖旺军,张鸣江,方永鑫. 131I-组合单克隆抗体局部放射免疫导向治疗肝癌的临床观察[J]. 解放军医学杂志, 2003, 28(10): 926-927 |
| |
| 作者姓名： | 蔡红兵 罗荣城 李爱民 张军一 廖旺军 张鸣江 方永鑫 |
| |
| 作者单位： | 510515,广州,第一军医大学南方医院 |
| |
| 摘 要： | 探讨13 1 I标记组合单克隆抗体S10 2、T9、CL 3(Cocktail法)局部导向治疗肝癌的近期疗效、毒副反应。采用IODO GEN法标记13 1I McAb,B超引导下经皮穿刺肿瘤局部注射 ,治疗 116例中晚期原发性肝癌 ,用量每次 5 0～ 70mCi。结果显示 ,本治疗有效率 (CR PR) 2 9 3%,总有效率(CR PR MR) 5 3 4 %,一年生存率 38 2 %,中位生存期 34 7周 ,中位疾病进展期 12周。表明13 1I标记组合单克隆抗体局部导向治疗原发性肝癌属于微创手术 ,经济、疗效确切、毒副反应小。
|
| 关 键 词： | 癌 肝细胞 放射免疫疗法 抗体 单克隆 |
| 修稿时间： | 2002-12-25 |
CLINICAL TRIALS OF PARTIAL RADIOIMMUNITY TARGETING THERAPY WITH 131I MONOCLONAL ANTIBODY FOR HEPATOCELLULAR CARCINOMA (HCC) |
| |
| Cai Hongbing,Luo Rongcheng,Li Aimin et al. CLINICAL TRIALS OF PARTIAL RADIOIMMUNITY TARGETING THERAPY WITH 131I MONOCLONAL ANTIBODY FOR HEPATOCELLULAR CARCINOMA (HCC)[J]. Medical Journal of Chinese People's Liberation Army, 2003, 28(10): 926-927 |
| |
| Authors: | Cai Hongbing Luo Rongcheng Li Aimin et al |
| |
| Affiliation: | Cai Hongbing,Luo Rongcheng,Li Aimin et al. Nanfang Hospital,First Military Medical University,Guangzhou 510515,China |
| |
| Abstract: | To explore the therapeutic effects and toxic side-effect of 131I-McAb (S102, T9, CL-3) in the treatment of hepatocellular carcinoma (HCC). 131I-McAb, which was labelled by IODO-GEN method, with 50-70mCi of 131I, was percutaneously injected into the tumor under B-ultrasonic guidance in 116 patients. The results showed that the effective rate (CR PR) was 29.3% (34/116), the overall effective rate (CR PR MR) was 53.4% (62/116), the one-year survival rate was 38.2% (39/102), the mean survival time was 34.7 weeks, and the mean tumor developing phase was 12 weeks. The results suggested that the use of 131I-McAb in the treatment of HCC is a low toxic, effective and minimal invasive operation. |
| |
| Keywords: | carcinoma hepatocellular radioimmunotherapy antibodies monoclonal |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
